Pacira Biosciences Inc PCRX:NASDAQ

Last Price$40.85Cboe Closing Price as of 3:59PM ET 7/15/19
Cboe Real-Time Quotes
Today's Change-0.43(1.04%)
Bid (Size)$40.92 (3)
Ask (Size)$40.93 (2)
Day Low / High$40.51 - 41.44
Volume274.4 K
  • Latest Stories
  • Commentary and Analysis
Insider Trends: Insider Sale at Pacira Biosciences Reducing 90-Days of Buying
5:50PM ET 7/12/2019 MT Newswires

David M Stack, Director and CEO & Chairman, reported a sale of 13,115 shares in Pacira Biosciences (PCRX) for $562,377 on Jul 08, 2019. Following the Form...

2019, 2020 Earnings Estimates for Pacira Biosciences Scaled Up
1:26AM ET 7/10/2019 MT Newswires

The 2019 and 2020 full year forecasted earnings estimates for Pacira Biosciences Inc's (NASDAQ:PCRX, Recent Price: 43.42) have been scaled up. The...

Pacira Pharma Says Using Its Painkiller in Wisdom Tooth Extraction Cuts Later Opioid Use
11:52AM ET 6/26/2019 MT Newswires

Pacira Pharmaceuticals' (PCRX) said its Exparel anesthetic, when given to dental patients getting wisdom teeth removed, reduced the use of post-surgery...

Pacira Pharmaceuticals Says European Agency Accepts Marketing Application for Post-Surgical Painkiller
8:06AM ET 6/25/2019 MT Newswires

Pacira Pharmaceuticals (PCRX) said pre-market Tuesday that the European Medicines Agency has approved the company's Marketing Authorization Application for...

Pacira Pharmaceuticals Names President
7:34AM ET 6/19/2019 MT Newswires

Pacira Pharmaceuticals (PCRX) said it named Max Reinhardt as the company's president. Reinhardt was most recently Vice President of Marketing for DePuy...

Pacira Pharmaceuticals Says Data Show Its Pain Medication Cuts Opioid Use After Hip Surgery
8:13AM ET 6/12/2019 MT Newswires

Pacira Pharmaceuticals (PCRX) reported that new data that show that patients receiving EXPAREL after hip replacement surgery had a reduction in opioid use,...

Analyst Actions: Barclays Initiates Coverage on Pacira Pharmaceuticals With Overweight Rating, $52 PT
11:37AM ET 6/11/2019 MT Newswires

Pacira Pharmaceuticals' (PCRX) average rating among analysts is a hold, with an average price target of $55. Price: 41.63, Change: -1.41, Percent Change:...

Pacira Pharmaceuticals Reports Efficacy & Safety of Treatment for Patients Undergoing Shoulder Arthroplasty
8:15AM ET 6/04/2019 MT Newswires

Pacira Pharmaceuticals (PCRX) said a multinational phase 3 study supported the efficacy and safety of exparel as a single-injection interscalene brachial...

Analysts Ratchet Up Expectations for Pacira Pharmaceuticals' Q2 and Full Year Earnings
7:26AM ET 5/11/2019 MT Newswires

Pacira Pharmaceuticals Inc's (NASDAQ:PCRX, Recent Price: 47.97) Q2 quarterly and full year forecasted earnings estimates for the periods ending June 30,...

2019 and 2020 Earnings Estimates for Pacira Pharmaceuticals Scaled Down
1:51AM ET 5/07/2019 MT Newswires

The 2019 and 2020 full year forecasted earnings estimates for Pacira Pharmaceuticals Inc's (NASDAQ:PCRX, Recent Price: 46.65) have been lowered. The...